Folotyn for Non-Hodgkin's Lymphoma Annapolis MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Jeanine Lori Werner, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Female
Languages
Spanish
Education
Medical School: Columbia Univ Coll Of Physicians And Surgeons, New York Ny 10032
Graduation Year: 1992
Hospital
Hospital: Anne Arundel Med Ctr, Annapolis, Md
Group Practice: Annapolis Medical Specialist

Data Provided by:
Dr.Curtis Harris
(410) 573-5300
2003 Medical Pkwy #210
Annapolis, MD
Gender
M
Speciality
Oncologist
General Information
Hospital: Aamc
Accepting New Patients: Yes
RateMD Rating
4.4, out of 5 based on 5, reviews.

Data Provided by:
Peter Robert Graze, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer), Hematology-Internal Medicine
Gender
Male
Education
Medical School: Harvard Med Sch, Boston Ma 02115
Graduation Year: 1971
Hospital
Hospital: Anne Arundel Med Ctr, Annapolis, Md
Group Practice: Annapolis Medical Specialist

Data Provided by:
Peter R Graze
(410) 573-5300
900 Bestgate Rd
Annapolis, MD
Specialty
Hematology / Oncology, Medical Oncology

Data Provided by:
Dr.Jason Taksey
(410) 573-5300
2003 Medical Pkwy #210
Annapolis, MD
Gender
M
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Angel Eduardo Torano, MD
(410) 897-5800
2002 Medical Pkwy
Annapolis, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Johns Hopkins Univ Sch Of Med, Baltimore Md 21205
Graduation Year: 1987

Data Provided by:
Jason David Taksey
(410) 573-5300
900 Bestgate Rd
Annapolis, MD
Specialty
Medical Oncology

Data Provided by:
Kevin Brian Knopf, MD
(410) 573-5300
900 Bestgate Rd Ste 300
Annapolis, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ca, San Francisco, Sch Of Med, San Francisco Ca 94143
Graduation Year: 1992

Data Provided by:
Kevin B Knopf
(410) 573-5300
900 Bestgate Rd
Annapolis, MD
Specialty
Hematology / Oncology

Data Provided by:
Ashish Kumar Chawla, MD
(443) 481-5800
2001 Medical Pkwy
Annapolis, MD
Specialties
Oncology (Cancer), Radiation Oncology
Gender
Male
Education
Medical School: Jefferson Med Coll-Thos Jefferson Univ, Philadelphia Pa 19107
Graduation Year: 1998

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com